探索纳米载体介导的药物递送治疗类风湿性关节炎(RA)的潜力。

IF 1.2 Q4 RHEUMATOLOGY
Shivani Pannu, Rahul Pal, Inderjeet Verma
{"title":"探索纳米载体介导的药物递送治疗类风湿性关节炎(RA)的潜力。","authors":"Shivani Pannu, Rahul Pal, Inderjeet Verma","doi":"10.2174/0115733971345399250529170645","DOIUrl":null,"url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a chronic autoimmune disorder that leads to severe joint damage, persistent inflammation, and an increase in synovial tissue. While existing treatment modalities such as corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and nonsteroidal anti-inflammatory drugs (NSAIDs) can alleviate symptoms, they frequently come with systemic side effects and do not always achieve satisfactory disease remission. Moreover, the broad distribution of these medications can result in off-target toxicity and inadequate drug levels at the affected joints. This study aims to explore the therapeutic capabilities of drug delivery systems (DDs) utilizing nanocarriers for RA management. The focus is on evaluating how these nanocarriers can facilitate targeted, efficient, and safer drug delivery by concentrating on inflamed joint tissues, minimizing systemic toxicity, and enhancing drug uptake at the disease site. This review analyzes various nanocarrier types, including liposomes, polymeric nanoparticles (NPs), dendrimers, micelles, and hybrid systems. A review of over 100 original research articles on RA treatment was conducted, drawing from platforms such as Google Scholar, ResearchGate, official websites, and raw data. The application of nanocarriers in RA therapy has demonstrated considerable potential in enhancing the precision and effectiveness of drug delivery. By enabling higher concentrations of medication directly at the inflammation site, nanocarrier-mediated drug delivery systems can mitigate systemic side effects and improve therapeutic outcomes. These systems present a promising approach to overcoming the limitations of current RA treatments, offering more targeted, efficient, and safer therapeutic alternatives. Nonetheless, additional research and development are essential to fully harness the capabilities of nanocarrier systems in RA treatment and to refine their clinical implementation.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploring the Therapeutic Potential of Nanocarrier-Mediated Drug Delivery in Rheumatoid Arthritis (RA) Treatment.\",\"authors\":\"Shivani Pannu, Rahul Pal, Inderjeet Verma\",\"doi\":\"10.2174/0115733971345399250529170645\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Rheumatoid arthritis (RA) is a chronic autoimmune disorder that leads to severe joint damage, persistent inflammation, and an increase in synovial tissue. While existing treatment modalities such as corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and nonsteroidal anti-inflammatory drugs (NSAIDs) can alleviate symptoms, they frequently come with systemic side effects and do not always achieve satisfactory disease remission. Moreover, the broad distribution of these medications can result in off-target toxicity and inadequate drug levels at the affected joints. This study aims to explore the therapeutic capabilities of drug delivery systems (DDs) utilizing nanocarriers for RA management. The focus is on evaluating how these nanocarriers can facilitate targeted, efficient, and safer drug delivery by concentrating on inflamed joint tissues, minimizing systemic toxicity, and enhancing drug uptake at the disease site. This review analyzes various nanocarrier types, including liposomes, polymeric nanoparticles (NPs), dendrimers, micelles, and hybrid systems. A review of over 100 original research articles on RA treatment was conducted, drawing from platforms such as Google Scholar, ResearchGate, official websites, and raw data. The application of nanocarriers in RA therapy has demonstrated considerable potential in enhancing the precision and effectiveness of drug delivery. By enabling higher concentrations of medication directly at the inflammation site, nanocarrier-mediated drug delivery systems can mitigate systemic side effects and improve therapeutic outcomes. These systems present a promising approach to overcoming the limitations of current RA treatments, offering more targeted, efficient, and safer therapeutic alternatives. Nonetheless, additional research and development are essential to fully harness the capabilities of nanocarrier systems in RA treatment and to refine their clinical implementation.</p>\",\"PeriodicalId\":11188,\"journal\":{\"name\":\"Current rheumatology reviews\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current rheumatology reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115733971345399250529170645\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current rheumatology reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115733971345399250529170645","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

类风湿性关节炎(RA)是一种慢性自身免疫性疾病,可导致严重的关节损伤、持续性炎症和滑膜组织的增加。虽然现有的治疗方式,如皮质类固醇、疾病改善抗风湿药物(DMARDs)和非甾体抗炎药(NSAIDs)可以缓解症状,但它们经常伴有全身副作用,并不能总能达到令人满意的疾病缓解。此外,这些药物的广泛分布可能导致脱靶毒性和受影响关节的药物水平不足。本研究旨在探讨利用纳米载体的药物输送系统(DDs)治疗类风湿性关节炎的能力。重点是评估这些纳米载体如何通过集中在发炎的关节组织,最小化全身毒性和增强疾病部位的药物摄取来促进靶向、有效和更安全的药物递送。本文分析了各种纳米载体类型,包括脂质体,聚合物纳米颗粒(NPs),树状大分子,胶束和混合系统。通过谷歌Scholar、ResearchGate等平台、官方网站和原始数据,对100余篇RA治疗相关的原创研究文章进行综述。纳米载体在类风湿性关节炎治疗中的应用在提高药物传递的准确性和有效性方面显示出相当大的潜力。纳米载体介导的药物传递系统可以在炎症部位直接使用更高浓度的药物,从而减轻全身副作用并改善治疗效果。这些系统为克服当前类风湿性关节炎治疗的局限性提供了一种有希望的方法,提供了更有针对性、更有效和更安全的治疗方案。尽管如此,为了充分利用纳米载体系统在类风湿关节炎治疗中的能力并完善其临床应用,进一步的研究和开发是必不可少的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploring the Therapeutic Potential of Nanocarrier-Mediated Drug Delivery in Rheumatoid Arthritis (RA) Treatment.

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that leads to severe joint damage, persistent inflammation, and an increase in synovial tissue. While existing treatment modalities such as corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and nonsteroidal anti-inflammatory drugs (NSAIDs) can alleviate symptoms, they frequently come with systemic side effects and do not always achieve satisfactory disease remission. Moreover, the broad distribution of these medications can result in off-target toxicity and inadequate drug levels at the affected joints. This study aims to explore the therapeutic capabilities of drug delivery systems (DDs) utilizing nanocarriers for RA management. The focus is on evaluating how these nanocarriers can facilitate targeted, efficient, and safer drug delivery by concentrating on inflamed joint tissues, minimizing systemic toxicity, and enhancing drug uptake at the disease site. This review analyzes various nanocarrier types, including liposomes, polymeric nanoparticles (NPs), dendrimers, micelles, and hybrid systems. A review of over 100 original research articles on RA treatment was conducted, drawing from platforms such as Google Scholar, ResearchGate, official websites, and raw data. The application of nanocarriers in RA therapy has demonstrated considerable potential in enhancing the precision and effectiveness of drug delivery. By enabling higher concentrations of medication directly at the inflammation site, nanocarrier-mediated drug delivery systems can mitigate systemic side effects and improve therapeutic outcomes. These systems present a promising approach to overcoming the limitations of current RA treatments, offering more targeted, efficient, and safer therapeutic alternatives. Nonetheless, additional research and development are essential to fully harness the capabilities of nanocarrier systems in RA treatment and to refine their clinical implementation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
82
期刊介绍: Current Rheumatology Reviews publishes frontier reviews on all the latest advances on rheumatology and its related areas e.g. pharmacology, pathogenesis, epidemiology, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in rheumatology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信